investor appear justifi concern alleg improp sales-practic regard
cancer insur polici sold japan earli stage view
reput issu earn issu although think
concern could linger main question appear quickli japan
restor trust custom base prevent downward pressur new sale
beyond current unclear whether improp sale cancer
insur product beyond japan post product expect
comprehens perspect issu upcom investor day new york
septemb meantim lower ep estim
price target new ep estimate
old estimate base expect overhang japan
japan provid consum postal well bank insur product
major distribut channel postal locat
account one-quart third-sector cancer supplement medic
insur new sale vast major revenu earn japan
remaind us
aflac expect new sale third- first-sector protect product
japan declin mid-teen percentag rang includ drop japan
sale previou guidanc low-to-mid single-digit percentag declin
third- first-sector new sale reflect challeng y/i comparison
compani current stanc japan still expect acquir
common share open market purchas part strateg allianc
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
lower usd
return equiti ttm
link barclay live interact chart
equal weight strong presenc
high-margin supplement insur market
includ domin busi japan howev
next sever year anticip slow top-
line growth stabl margin modest ep
one highest roe life insur
industri upsid case assum multipl
ep
risk includ slower anticip econom
recoveri weak employ trend japan
 fx invest portfolio write-down
downsid case assum multipl
ep
mn except per invest invest fx defer polici acquisit oper benefit oper earn hedg cost referencehedg cost relat foreign currenc invest cost relat foreign currenc invest rate hedg hedg cost earn ex hedg cost impact net earn realiz invest gain non-recur incom incom tax expens benefit item ex op net adjust per share metricsoper impact net earn invest gain non-recur incom tax expens benefit item ex op impact per ep ex currenc ep ex currenc impact non-recur basic share dilut share share per pay-out ratiostot benefit oper oper profit oper profit margin incl hedg oper profit margin ex hedg percent invest oper oper earn ep growth ex currenc valu per share ex valu per share ex aoci link qtr valu per share ex unreal inv valu per share ex unreal inv qtr chang book valu per share bv per share ex bv per share ex unreal inv roe ex roe ex unreal inv roe ex oper roe ex tax invest portfolio yield rate share amt share amt common capit capit return annual normal barclay inc
jay gelb cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
unless otherwis indic price sourc refinitiv reflect close price relev trade market may last
avail price time public
barclay bank plc and/or affili lead manag co-lead manag publicli disclos offer secur issuer
 employe non-execut director barclay plc director issuer
cd barclay bank plc and/or affili market-mak debt secur issu issuer
ce barclay bank plc and/or affili market-mak equiti secur issu issuer
barclay bank plc and/or affili receiv compens invest bank servic issuer past month
 barclay bank plc and/or affili expect receiv intend seek compens invest bank servic issuer
within next month
fa barclay bank plc and/or affili benefici own class equiti secur issuer calcul accord
us regul
fb barclay bank plc and/or affili benefici own long posit class equiti secur issuer
calcul accord eu regul
fc barclay bank plc and/or affili benefici own short posit class equiti secur issuer
calcul accord eu regul
gd one analyst fundament credit coverag team member household financi interest debt
equiti secur issuer
ge one analyst fundament equiti coverag team member household financi interest debt
equiti secur issuer
 issuer benefici own class common equiti secur barclay plc
barclay bank plc and/or affili parti agreement issuer provis financi servic barclay bank plc and/or
affili
 barclay bank plc and/or affili liquid provid and/or trade regularli secur issuer and/or relat
 barclay bank plc and/or affili receiv non-invest bank relat compens includ compens brokerag
servic applic issuer within past month
